<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094090</url>
  </required_header>
  <id_info>
    <org_study_id>PXL-2211</org_study_id>
    <nct_id>NCT04094090</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia</brief_title>
  <official_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goodman Eye Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goodman Eye Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing&#xD;
      corneal cross-linking (CXL) for the treatment of ectatic disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for&#xD;
      post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal&#xD;
      crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery.&#xD;
      Patients will undergo monitoring for 1 year, with serial measurements of corneal topography,&#xD;
      visual acuity, intraocular pressure, pachymetry, and visual function questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2019</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2029</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected distance visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>change in corrected distance visual acuity (CDVA) at the last required study visit (6 months post-op), compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Change in UCVA at 6 months, compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Keratometry</measure>
    <time_frame>1 year</time_frame>
    <description>Change in Kmax, compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Keratoconus</condition>
  <condition>Pellucid Marginal Corneal Degeneration</condition>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mW, 10 sec on, 10 sec off, 22.5 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pusled, accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mW, 10 sec on, 10 sec off, 11.25 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</intervention_name>
    <description>Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea</description>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
    <arm_group_label>Pusled, accelerated</arm_group_label>
    <other_name>Corneal crosslinking</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who have one or both eyes that meet criteria 1 and 1 or more of the following&#xD;
        criteria will be considered candidates for this study:&#xD;
&#xD;
        1.10 years of age or older 2. Presence of central or inferior steepening 3. Axial&#xD;
        topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal&#xD;
        degeneration 4. Presence of one or more findings associated with keratoconus or pellucid&#xD;
        marginal degeneration, such as:&#xD;
&#xD;
          1. Fleischer ring&#xD;
&#xD;
          2. Vogt's striae&#xD;
&#xD;
          3. Decentered corneal apex&#xD;
&#xD;
          4. Munson's sign&#xD;
&#xD;
          5. Apical Corneal scarring consistent with Bowman's breaks&#xD;
&#xD;
          6. Scissoring of the retinoscopic reflex&#xD;
&#xD;
          7. Crab-claw appearance on topography 5. Steepest keratometry (Kmax) value â‰¥ 47.20 D 6.&#xD;
             I-S keratometry difference &gt; 1.5 D on the Pentacam map or topography map 7. Posterior&#xD;
             corneal elevation &gt;16 microns 8. Thinnest corneal point &gt;300 microns 9. Contact Lens&#xD;
             Wearers Only:&#xD;
&#xD;
        a. Removal of contact lenses for the required period of time prior to the screening&#xD;
        refraction: Contact Lens Type Minimum Discontinuation Time Soft or Scleral 3 days Rigid gas&#xD;
        permeable 2 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects meeting any of the following criteria will be excluded from this study:&#xD;
&#xD;
          1. Eyes classified as either normal or atypical normal on the severity grading scheme.&#xD;
&#xD;
          2. Corneal pachymetry at the screening exam that is &lt;300 microns at the thinnest point in&#xD;
             the eye(s) to be treated.&#xD;
&#xD;
          3. Previous ocular condition (other than refractive error) in the eye(s) to be treated&#xD;
             that may predispose the eye for future complications, for example:&#xD;
&#xD;
               1. History of or active corneal disease (e.g., herpes simplex, herpes zoster&#xD;
                  keratitis, recurrent erosion syndrome, acanthomeoeba, etc.)&#xD;
&#xD;
               2. Clinically significant corneal scarring in the CXL treatment zone that is not&#xD;
                  related to keratoconus or, in the investigator's opinion, will interfere with the&#xD;
                  cross-linking procedure.&#xD;
&#xD;
          4. Pregnancy (including plan to become pregnant) or lactation during the course of the&#xD;
             study&#xD;
&#xD;
          5. A known sensitivity to study medications&#xD;
&#xD;
          6. Patients with nystagmus or any other condition that would prevent a steady gaze during&#xD;
             the CXL treatment or other diagnostic tests.&#xD;
&#xD;
          7. Patients with a current condition that, in the physician's opinion, would interfere&#xD;
             with or prolong epithelial healing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Goodman Eye Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel F Goodman, MD</last_name>
      <phone>415-474-3333</phone>
      <email>swong@goodmaneyecenter.com</email>
    </contact>
    <investigator>
      <last_name>Daniel F Goodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will be held in a secure location. While summary outcomes data will be provided on request to other researchers and periodically at scientific conferences, protected health information will not.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT04094090/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

